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Dendritic cells (DCs) are key regulators of
innate and acquired immunity. The matu-
ration of DCs is directed by signal trans-
duction events downstream of toll-like
receptors (TLRs) and other pattern recog-
nition receptors. Here, we demonstrate
that, in mouse DCs, TLR agonists stimu-
late a profound metabolic transition to
aerobic glycolysis, similar to the Warburg
metabolism displayed by cancer cells.
This metabolic switch depends on the
phosphatidyl inositol 3-kinase/Akt path-
way, is antagonized by the adenosine
monophosphate (AMP)–activated protein
kinase (AMPK), and is required for DC
maturation. The metabolic switch in-
duced by DC activation is antagonized by
the antiinflammatory cytokine interleukin-10.
Our data pinpoint TLR-mediated meta-
bolic conversion as essential for DC matu-
ration and function and reveal it as a
potential target for intervention in the
control of excessive inflammation and
inappropriately regulated immune re-
sponses. (Blood. 2010;115(23):4742-4749)
Introduction
Toll-like receptor (TLR)–directed dendritic cell (DC) activation is
critical for the tailoring of immune responses to specific patho-
gens.1,2 TLR agonists initiate profound changes in DCs, which
without undergoing cellular division transition from a resting state
into an activated mature state.3,4 This process involves large-scale
changes in the expression of genes encoding a broad array of
proteins, including but not limited to cytokines, chemokines, and
costimulatory molecules,5 and behavioral changes that result in
DCs migrating into T-cell areas within lymphoid organs.6
We hypothesized that, like growth factors, TLR agonists might
not only direct new gene transcription but also affect changes in
cellular metabolic pathways to ensure that sufficient bioenergetic
and metabolic resources exist to support programs of new gene
expression.7,8 Consistent with this, signaling pathways elicited by
TLRs share elements with those used by growth factor receptors.
For example, TLRs have been shown to initiate phosphatidyl
inositol 3-kinase (PI3K)/Akt activation in a variety of cell types,
including DCs,9,10 although the full consequences of this remain
unclear. Moreover, in macrophages TLR ligation initiates auto-
phagy,11,12 a process that contributes to the killing of pathogens
within cells, but also provides metabolic intermediates to maintain
bioenergetics and promote cell survival.
Here, we show that after exposure to TLR agonists, DCs
undergo a metabolic transition from oxidative phosphorylation
(OXPHOS) to aerobic glycolysis. This process underpins the
activation pathway, because its inhibition results in a failure of DCs
to mature. The metabolic switch is promoted by PI3K/Akt signal-
ing and is inhibited by the adenosine monophosphate (AMP)–
activated protein kinase (AMPK), a central regulator of catabolic
metabolism and OXPHOS,13 and by the antiinflammatory cytokine
interleukin-10 (IL-10).14 Collectively, the data implicate DC meta-
bolic reprogramming as an underlying control point for the
inflammatory processes and adaptive immune responses induced
by this important cell type.
Methods
Mice and reagents
C57BL6 (B6) mice were purchased from The Jackson Laboratory, and
akt1/ mice (a gift from Dr M. Birnbaum, University of Pennsylvania) and
DO11.10 mice were bred and maintained under specific pathogen-free
conditions at the University of Pennsylvania under protocols approved by
the Institutional Animal Care and Use Committee. Heat-killed Propionibac-
terium acnes (PA) was purchased from The Van Kampen Group. Cytosine
phosphate guanine oligodeoxynucleotide 1826 was obtained from Coley
Pharmaceuticals. Lipopolysaccharide (LPS; Escherichia coli serotype
0111:B4) was from Sigma-Aldrich. Inhibitors and activators were from
Sigma-Aldrich. Golgi-Plug (brefeldin) and antibodies for flow cytometry,
enzyme-linked immunoabsorbent assays, and against IL-10 receptor (IL-
10R) were from BD PharMingen. MitoTrackers were from Invitrogen. Total
and phosphospecific Akt and AMPK antibodies were from Cell Signaling
Technologies. All media components were from Mediatech.
DC culture and retroviral transduction
Bone marrow–derived DCs were generated as described.15 Briefly, bone
marrow DC precursors were differentiated in the presence of granulocyte-
macrophage colony-stimulating factor (GM-CSF; 20 ng/mL) in complete
DC media (RPMI containing 10% fetal calf serum, 100 U/mL penicillin/
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streptomycin, 0.05mM basal medium Eagle, and 2mM L-glutamine).
Retroviral transduction of DCs was accomplished as described previ-
ously.16 Sequences for AMPK short hairpin RNAs (shRNAs) were obtained
from Open Biosystems and cloned into LMP retroviral vectors; the shRNAs
were highly effective as judged by their ability to knockdown AMPK levels
in mouse embryonic fibroblasts (supplemental Figure 6, available on the
Blood Web site; see the Supplemental Materials link at the top of the online
article). Empty (vector) or recombinant retroviruses were obtained after the
transfection of 293T packaging cells with the use of Lipofectamine
(Invitrogen); retrovirus-containing supernatants were collected 48 hours
after transfection and used for spin infection (2500 rpm, 2 hours) of day
1 bone marrow DC cultures in 6-well plates. After an additional 7 to 8 days
in culture with GM-CSF, DCs were harvested, and transduction efficiency
was assessed with the use of anti–human CD8 antibody (Ab) and flow
cytometry; we typically obtained transduction rates greater than 80%. On
days 8 to 10 of culture, DCs were washed into complete DC media
containing 5 ng/mL GM-CSF and various concentrations of glucose or
2-deoxyglucose and were maintained in medium alone or pulsed for
18 hours with heat-killed PA (10 g/mL), cytosine phosphate guanine
oligodeoxynucleotide 1826 (1 g/mL), or LPS (100 ng/mL). In some
experiments IL-10 (50 ng/mL), monoclonal (mAb) anti–IL-10R (30 g/
mL), LY294002 (5 or 10M; Sigma-Aldrich), or 5-aminoimidazole-4-
carboxamide ribonucleotide (AICAR; 1mM) were added to DC cultures.
Western blotting
Cell lysate preparation, sodium dodecyl sulfate–polyacrylamide gel electro-
phoresis, electrophoretic transfer, immunoblotting, and development with
enhanced chemiluminescence were accomplished as described previously.17
Cytokine measurements and flow cytometry
Intracellular cytokine staining and staining for costimulatory molecules and
major histocompatibility complex II were performed with specific fluoro-
chrome-labeled mAbs and flow cytometry, as described.2 Mitochondrial
mass and potential were measured with the use of MitoTracker Green FM
and MitoTracker Red CMXRos, respectively, and flow cytometry according
to the manufacturer’s instructions. Cytokines in DC supernatants were
measured by capture enzyme-linked immunoabsorbent assays with the use
of paired mAbs and recombinant standards, as described.18
In vivo T-cell responses
Mice were adoptively transferred with 5  106 5,6-carboxyfluorescein
diacetate, succinimidyl ester (CFSE)–labeled DO11.10 splenocytes intrave-
nously and 1 day later injected subcutaneously into one rear footpad with
5  105 washed DCs that had previously been cultured in medium alone,
ovalbumin (OVA) alone (300 g/mL endotoxin-free egg white), OVA plus
LPS (100 ng/mL), or OVA plus LPS in the presence of 2-deoxyglucose
(2-DG; 10mM) for 6 hours. Four days later, mice were killed, and popliteal
lymph nodes (LNs) were harvested. Single-cell suspensions were stained
with fluorochrome-conjugated mAb specific for the DO11.10 clonotype
(KJ126) and CD4 and were analyzed by flow cytometry. In some
experiments, mice were injected subcutaneously into one rear footpad with
5  105 washed, CFSE-labeled DCs that had previously been treated as
described in this section. Two days later draining popliteal LNs were
isolated, and CD11c CFSE-labeled cells were analyzed by flow cytometry.
Real-time RT-PCR
DCs were pulsed with different stimuli, as described in “In vivo T-cell
responses,” for 6 hours before RNA extraction. RNA was extracted with RNeasy
(QIAGEN) and treated with DNase I (Invitrogen). Oligo (dT) (Promega) and
Superscript II (Invitrogen) were used to synthesize first-strand cDNAs from
equivalent amounts of RNA from each sample. Real-time reverse transcription–
polymerase chain reaction (RT-PCR) was performed in a 7500 Fast Real-Time
PCR System (Applied Biosystems) with SYBR green RT-PCR master mix
(Applied Biosystems). Data were generated with the comparative threshold cycle
(CT) method by normalizing to hypoxanthine phospho ribosyl transferase.
Sequences of primers used in the studies are available on request.
Metabolic assays
The glycolytic rate of DCs was determined by measuring the conversion of
5-3H-glucose to tritiated water, as described previously.19 Immature DCs
were plated at 1  106/mL in 24-well plates and left unstimulated or
stimulated with various TLR ligands for 14 to 16 hours. Cells were
harvested, washed twice, and resuspended in glucose-free medium (RPMI;
Gibco), and then incubated with 10 Ci (0.037 Bq) of 5-3H-glucose
(Perkin-Elmer) at 37°C for 1 hour. The reaction was stopped by adding HCl
(0.1M final). [3H]2O generated by enolase activity was separated from
5-3H-glucose by diffusion, and counts were measured with the use of a 1450
Microbeta scintillation counter (Wallac). The glycolytic rate for each
sample was normalized relative to that of unstimulated, immature DCs
within each experiment and expressed as fold increase. Glucose and lactate
levels in culture medium were measured with the use of a BioProfile FLEX
analyzer (NOVA Biomedical).
Measurement of mitochondrial-dependent -oxidation of fatty acids
was conducted as previously described with modifications.20 In brief,
1  106 DCs were left unstimulated or stimulated with 100 ng/mL LPS for
14 hours. [9,10-3H]-palmitic acid complexed to bovine serum albumin
(essentially fatty acid free; Sigma-Aldrich) was added to the DC cultures
and incubated for 6 hours. Mitochondrial-independent -oxidation was
assessed by measuring [9,10-3H]-palmitate oxidation in the presence of
200M etomoxir (Sigma-Aldrich), an irreversible inhibitor of carnitine
palmitoyltransferase I, the rate-limiting enzyme for mitochondrial import of
long-chain fatty acids. Supernatant was applied to ion-exchange columns
(Dowex 1  8-200; Sigma-Aldrich), and tritiated water was recovered by
eluting the columns with water. One-fifth of the recovered tritiated water
was then used for scintillation counting. The rate of -oxidation was
calculated as the difference between oxidation counts in the presence or
absence of etomoxir and was expressed as count per minute per 1  106
cells.
The rate of oxygen consumption by LPS-activated DCs was determined
as previously described with the use of a water-jacketed, air-tight oximeter
(Hansatech).21 OXPHOS-dependent oxygen consumption was calculated as
the difference between the total rate of oxygen consumption and the rate in
the presence of 5M oligomycin, an inhibitor of mitochondrial adenosine
triphosphate (ATP) synthase.
Statistics
Statistical significance was calculated with the Student t test.
Results
DC activation by TLR ligands induces a metabolic switch to
glycolytic metabolism
To determine whether TLR activation has effects on glycolytic
metabolism, DCs were activated by various TLR ligands and
analyzed for their ability to metabolize glucose, the primary
substrate for ATP generation through glycolysis. Stimulation of
DCs by TLR4, TLR2, and TLR9 promoted a significant increase in
the glycolytic rate (2- to 4-fold) relative to resting controls (Figure
1A). Increased glycolysis requires greater usage of glucose, and in
other cells this is facilitated by the increased expression of glucose
transporters at the plasma membrane.22 Consistent with this,
increased levels of glucose transporter 1 transcripts (Figure 1B)
and protein (supplemental Figure 1) were observed after TLR
stimulation of DCs. Both glucose consumption and the production
of lactate, a metabolic end point of aerobic glycolysis, increased
after LPS stimulation of DCs (Figure 1C-D), indicating an increase
in glycolytic activity after TLR stimulation.
The up-regulation of glycolysis after DC activation prompted us
to examine other metabolic pathways affected by TLR stimulation.
Fatty acid -oxidation by mitochondria is an important catabolic
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energy-generating pathway used for homeostatic processes in
unstressed and resting cells.20 We found that the rate of
mitochondrial-dependent -oxidation of free fatty acids was signifi-
cantly suppressed after TLR activation (Figure 1E). Although
overall oxygen consumption by DCs did not dramatically change
after LPS stimulation, lower rates of mitochondrial-dependent
oxygen consumption were observed (Figure 1F). Consistent with
this reduction in mitochondrial oxygen consumption, mitochon-
drial potential also decreased after exposure to LPS (Figure 1G).
This occurred in the absence of any change in mitochondrial mass
(Figure 1H). Taken together, these data indicate that TLR agonists
promote a profound metabolic switch in resting immature DCs
from mitochondrial -oxidation and OXPHOS to aerobic glycoly-
sis (Figure 1I). This switch to glycolysis despite ample oxygen to
support OXPHOS is reminiscent of the metabolic switch induced
on transformation (the “Warburg effect”).
PI3K/Akt signaling controls the metabolic switch to
aerobic glycolysis
The induction of glycolysis by growth factor receptors depends on
signal transduction mediated by the PI3K/Akt pathway.22,23 The
PI3K/Akt pathway was examined directly for its role in TLR-
induced glycolysis in DCs. LPS-induced glycolysis was signifi-
cantly reduced in DCs treated with the PI3K inhibitor LY294002
(Figure 2A) and in DCs lacking Akt1 (Figure 2B). In contrast, DCs
retrovirally transduced to express an active form of Akt24 exhibited
increased background levels of glycolysis and a heightened glyco-
lytic response to LPS (Figure 2C). The PI3K/Akt pathway was also
examined for its role in regulating the TLR-induced suppression of
mitochondrial-dependent -oxidation of fatty acids. Interestingly,
the suppression of mitochondrial fatty acid -oxidation triggered
by LPS was unaffected by the inhibition of PI3K by LY294002
(Figure 2D), the absence of Akt1 (Figure 2E), or the expression of
the active form of Akt (Figure 2F). These findings show that the
PI3K/Akt pathway plays a pivotal role in regulating glycolytic
metabolism in TLR-stimulated DCs but is dispensable for the
accompanying down-regulation of mitochondrial -oxidation.
Glycolysis is essential for cellular activation and survival after
exposure to TLR agonists
The engagement of aerobic glycolysis by growth factor signaling
allows cells to meet the bioenergetic demands of cellular prolifera-
tion.25 Although TLR signaling, like growth factor signaling, leads
to increases in glycolytic metabolism, it does not promote DC
proliferation. This implies that the metabolic changes, and specifi-
cally the increase in glycolysis triggered by TLRs, serve to meet the
Figure 1. DC activation by TLR ligands induces a
metabolic switch to aerobic glycolysis. (A) Glycolytic
rate of DCs after18 hours of culture in medium alone (-) or
with the TLR4, TLR2, and TLR9 ligands, LPS, heat-killed
PA or cytosine phosphate guanosine (CpG). (B) Glucose
transporter 1 (GLUT1) expression by DCs analyzed by
quantitative RT-PCR. (C) Glucose consumption by rest-
ing (-) and LPS-activated DCs. (D) Lactate production by
resting (-) and LPS-activated DCs. (E) Rate of mitochon-
drial fatty acid -oxidation in DCs cultured for 18 hours in
medium alone (-) or after stimulation with LPS.
(F) Mitochondrial O2 consumption of resting (-) or LPS-
stimulated DCs. (G) Mitochondrial potential, as assessed
by fluorescence with the MitoTracker Red CMXRos.
(H) Mitochondrial mass, assessed by fluorescence with
the MitoTracker Green FM. (G-H) The y-axis indicates
cell number. (I) The glycolysis/-oxidation ratio for DCs
stimulated with LPS. Bars represent mean values SDs
from 3 independent replicates; *P 	 .05 compared with
unstimulated controls (-). All data are representative of
2 to 4 independent experiments.
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bioenergetic demands of other biologic processes initiated by TLR
ligation. To explore this issue, we asked whether glucose metabo-
lism is essential for the maintenance of DC viability after activation
by TLRs. This seemed feasible, based on a previous report that DC
viability is linked to growth factor–dependent activation of Akt
signaling26 coupled with our data showing that Akt regulates
glycolytic metabolism in DCs (Figure 2). To address this question
DC viability after stimulation with LPS was examined under
conditions of glucose limitation. DCs activated by various LPS
concentrations displayed little cell death under normal glucose
conditions (10mM; Figure 3A). However, when stimulated in
limited glucose (2mM), DC viability decreased significantly in an
activation-dependent manner (Figure 3A). Analysis over time
showed that the increased death of DCs subjected to glucose
limitation was probably an acceleration of death normally observed
in DC cultures containing 10mM glucose (Figure 3B), raising the
possibility that the DCs were dying after the consumption of
available glucose. To test this, DCs were activated in medium
containing 10mM glucose, and on day 2 after stimulation the
cultures were fed with media containing either 10mM or 0mM
glucose, or the existing cultures were supplemented with a bolus of
glucose (10mM final concentration). Feeding DCs with glucose-
sufficient media or supplementation with glucose alone was
sufficient to maintain DC viability, whereas DC cultures fed with
glucose-free medium underwent apoptosis (Figure 3C). Together
the data indicate that glucose is an essential nutrient required for
the survival of activated DCs.
Activated DCs produce cytokines that initiate inflammation and
help tailor ensuing T-cell responses and express costimulatory
molecules that promote interaction with, and activation of, T cells.
The requirement for glucose metabolism to enact these processes
was explored by examining DC activation under reduced glucose
availability. TLR ligand–induced production of p40, the common
subunit of the inflammatory cytokines IL-12 and IL-23, was
significantly reduced in the absence of glucose (Figure 3D); the
same was true for tumor necrosis factor-
 (supplemental Figure 2).
To exclude the possibility that differences in cytokine production in
the absence of glucose was the direct consequence of diminished
cell numbers due to cell death, DCs were examined for intracellular
cytokine expression 5 hours after stimulation, at which time there is
little difference in viability between cells cultured with or without
glucose (data not shown). In the absence of glucose, LPS-
stimulated DCs showed a profound defect in the production of p40
and the up-regulation of the costimulatory molecule CD86, show-
ing that glucose metabolism is essential for DC function (supple-
mental Figure 3). Likewise, reduced glucose negatively effected
baseline expression of CD40 and the ability to up-regulate surface
expression of this molecule in response to LPS or PA (supplemental
Figure 4). To assess whether inhibition of glycolytic metabolism
could affect DC function even when glucose is freely available,
DCs were stimulated in the presence of the glycolytic inhibitor
2-deoxyglucose (2-DG). 2-DG profoundly blocked the TLR-
dependent expression of CD40 (Figure 3E), as well as of CD86 and
major histocompatibility complex II (supplemental Figure 5) in a
dose-dependent fashion.
To assess the functionality of DCs activated under conditions in
which glycolysis is inhibited, the ability of these cells to induce
T-cell responses in vivo was measured. DCs were pulsed with OVA
alone, or with OVA plus LPS, or OVA plus LPS in medium
containing 2-DG for 6 hours, then washed, and injected into the
footpads of mice into which CFSE-labeled DO11.10 CD4 T cells
had been transferred the day previously. Three days later, draining
popliteal LNs were analyzed by flow cytometry to assess the
proliferative response of DO11.10 cells. As expected, DCs that had
not been pulsed with OVA failed to activate these cells (Figure 3F
top). Consistent with their mature phenotype, and the known
adjuvant effects of LPS, DCs pulsed with OVA plus LPS induced a
markedly stronger T-cell response than did DCs pulsed with OVA
alone as measured by CFSE dye dilution of proliferating DO11.10
T cells (Figure 3F). Inclusion of 2-DG during incubation of DCs
with OVA plus LPS negated the effects of LPS; T-cell responses
induced by these cells were no different from those induced by DCs
incubated with OVA alone (Figure 3F).
With the use of CFSE-labeled DCs we tracked whether cells
that had been activated under conditions in which glycolysis was
inhibited were capable of migrating from the site of injection to the
LN and surviving over 2 days. As anticipated, more LPS-activated,
OVA-pulsed DCs were present in the LN than was the case for DCs
pulsed with OVA in the absence of LPS (Figure 3F bottom). 2-DG
treatment had an inhibitory effect on numbers of LPS-activated
OVA-pulsed DCs that were recoverable in the draining LN but did
not completely negate the effects of LPS in this regard (Figure 3F).
Figure 2. TLRs induce glycolytic metabolism in DCs
through the PI3K/Akt pathway. (A) Glycolytic rate of
DCs stimulated with LPS in the presence of the indicated
concentrations of the PI3K inhibitor LY294002. (B) Glyco-
lytic rate after LPS stimulation in akt1/ and akt1/
DCs. The fold change in glycolytic rate was calculated
relative to the untreated control for each genotype.
(C) Glycolytic rate of DCs transduced with the retroviral
vectors MIG (control) or MIG–active form of Akt (myr-
Akt). The data represent the fold increase in glycolytic
rate relative to unstimulated MIG-transduced DCs.
(D) Rate of mitochondrial fatty acid -oxidation in DCs
cultured for 18 hours in medium alone (-) or after
stimulation with LPS in the presence or absence of the
PI3K inhibitor LY294002. (E) Rate of mitochondrial fatty
acid -oxidation in wild-type (akt1/) or Akt-deficient
(akt1/) DCs cultured for 18 hours in medium alone (-)
or after stimulation with LPS. (F) Rate of mitochondrial
fatty acid -oxidation in DCs transduced with empty
vector (MIG) or expressing myr-Akt. Bars represent
mean value of replicates. Error bars represent SDs. All
data are representative of 2 or more independent experi-
ments.
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Taken together, these data suggest that initiating glycolytic metabo-
lism at the time of DC activation is important for full DC
maturation and subsequent survival and suggest that this metabolic
switch broadly underpins the functional changes induced by TLR
ligation in DCs required to initiate adaptive immunity.
AMPK antagonizes DC activation
Our data indicate that resting DCs predominantly use a catabolic
program of lipid -oxidation/OXPHOS for energy generation and
that this pathway is down-regulated after TLR-mediated activation
(Figure 1). AMPK is a central regulator of catabolic metabolism
and OXPHOS in eukaryotic cells.13 To assess whether the increased
rates of OXPHOS in resting DCs correlate with AMPK activity we
measured the level of AMPK activation after TLR stimulation.
AMPK is hyperphosphorylated on Thr-172 in its activation loop
(Figure 4A) in resting DCs, and AMPK phosphorylation dimin-
ished rapidly after exposure to LPS (Figure 4A). The rapid
suppression of AMPK signaling during DC activation led us to
hypothesize that AMPK may function to antagonize DC activation.
To assess this possibility, AMPK expression was suppressed in
DCs through introduction of shRNAs targeting both the 
 1 and 
 2
subunits of AMPK by retroviral-mediated gene transfer (supplemen-
tal Figure 6). Reduction of AMPK levels promoted an increase in
LPS-induced DC activation as measured by expression of IL-
12p40 and CD86 (Figure 4B). Activation of AMPK in DCs through
the administration of AICAR, a small molecule activator of AMPK,
inhibited LPS-mediated IL-12p40 expression (Figure 4C). More-
over, AICAR-treated DCs displayed decreased rates of LPS-
stimulated glucose consumption. AICAR was as effective as 2-DG,
a glycolytic inhibitor, in inhibiting LPS-induced glucose consump-
tion by DCs (Figure 4D). Together these data suggest that AMPK, a
known inducer of catabolic metabolism, antagonizes TLR-induced
DC maturation and does so, in part, by inhibiting the metabolic
switch to glycolysis triggered by TLR stimulation.
IL-10, an inhibitor of DC activation, blocks the switch to
glycolytic metabolism
Consistent with their central role in the initiation of potentially
dangerous innate and adaptive responses, DCs and their activation
are targeted for regulation by both immune system mediators and
pathogen-derived molecules. IL-10 is a potent inhibitor of DC
activation made by the immune system.14 The similarity between
the effects of IL-10 and the inhibition of the switch to glycolytic
metabolism on TLR-driven DC activation suggested that the two
might be linked. To assess this possibility, LPS-induced glycolysis
was measured in DCs cultured with recombinant IL-10 or in the
Figure 3. Glycolysis is essential for cellular activation and
survival after exposure to TLR agonists. (A) Survival of DCs
2 days after stimulation with LPS in 10mM or 2mM glucose.
(B) Survival of DCs over time after stimulation with LPS in media
containing either 10mM or 2mM glucose. Data points represent
the percentage of 7-amino-actinomycin D (7AAD)–positive cells
as determined by flow cytometry. (C) Survival of DCs after glucose
supplementation. DCs were cultured for 2 days in the presence of
10mM glucose. On day 2, the media was either left unchanged
(not fed) or supplemented with 10mM glucose (bolus) or replaced
with media containing 10 or 0mM glucose. Cell viability was
determined 24 hours later by 7AAD uptake. (A-C) Error bars are
SDs from triplicate measurements. (D) Cytokine (p40) production
by DCs in response to TLR agonists in the presence or absence of
glucose. Cytokine production was determined by enzyme-linked
immunoabsorbent assay 18 hours after activation. (E) LPS-
induced activation of DCs in the presence of the glycolytic inhibitor
2-DG. Flow cytometry was used to measure surface expression of
CD40 after LPS stimulation in the presence of the indicated
concentrations of 2-DG. Unstimulated DCs cultured in the ab-
sence of 2-DG or LPS are shown for comparison (-). Numbers
represent the percentage of cells staining positive for CD40.
(F top) DO11.10 CD4 T-cell proliferative responses, measured
by CFSE-dilution, in adoptively transferred mice immunized
4 days previously with DCs alone (-), or DCs pulsed with OVA
alone, DCs pulsed with OVA plus LPS, or DCs pulsed with OVA
plus LPS in the presence of 10mM 2-DG. Plots are gated on
KJ126CD4 cells. (F bottom) Numbers of CFSE-stained CD11c
cells in LNs draining sites of injection 2 days previously with
CFSE-labeled DCs pulsed with OVA alone, pulsed with OVA plus
LPS, or pulsed with OVA plus LPS in the presence of 10mM 2-DG.
The panel to the right shows the absence of CFSE signal in control
popliteal LNs draining noninjected sites. Bars indicate CFSE-
positive cells. All data are representative of 2 to 5 independent
experiments.
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presence of an Ab against the IL-10R, which blocks the effects of
endogenous IL-10 made by TLR ligand–activated DCs.27 TLR-initiated
glycolytic metabolism was inhibited in the presence of IL-10 and
increased when IL-10 feedback was blocked (Figure 5A), suggesting
that IL-10 negatively regulates glycolytic metabolism in DCs.
IL-10 has been reported to inhibit LPS-induced Akt phosphory-
lation,9 suggesting one possible mechanism by which IL-10 may
block TLR-induced glycolysis. However, we were unable to detect
a measurable effect of IL-10 on AKT phosphorylation (data not
shown). Because AMPK activation can block TLR-induced stimu-
lation of glycolytic metabolism in DCs, and AMPK activation is
negatively regulated by LPS, we assessed the effects of IL-10
signaling on AMPK activation. IL-10 by itself did not display a
profound effect on AMPK activation but was found to antagonize
the LPS-induced hypophosphorylation of AMPK (Figure 5B).
The observation that IL-10 can inhibit TLR-mediated glycolysis
in DCs raises the possibility that the inhibitory effects of 2-DG and
AICAR on DC maturation (Figures 3-4) may simply be the result
of autocrine IL-10 production by DCs. To address this issue, we
examined the effects of these small molecules on LPS-induced DC
activation with the use of DCs derived from IL-10/ mice. The
activation of IL-10–deficient DCs, as measured by LPS-stimulated
CD40 expression, was profoundly inhibited by 2-DG and AICAR
(Figure 5C). Similarly, the production of p40 (Figure 5D) and
tumor necrosis factor-
 (supplemental Figure 7) was inhibited by
2-DG in IL-10/ DCs, suggesting that the effect of glycolytic
inhibition on DC activation is IL-10 independent. Interestingly,
IL-10 production by wild-type DCs in response to LPS was also
suppressed by 2-DG and AICAR (supplemental Figure 8). To-
gether, these data suggest that DCs respond to IL-10 by retaining a
metabolic profile that is incompatible with enactment of the
activation pathway.
Figure 4. AMPK antagonizes DC activation. (A) Extracts of DCs stimulated with
LPS for the times shown were probed by Western blotting with antibodies specific for
phosphorylated Thr-172 AMPK
 or for total AMPK
. (B) LPS-induced maturation,
measured as p40 production and CD86 expression, as measured by flow cytometry
in DCs transduced with AMPK shRNAs or control Luc shRNAs. (-) denotes resting
DCs; numbers indicate percentage of CD11c cells within gates. (C) p40 production
by resting DCs (-) and DCs stimulated with LPS or LPS plus AICAR. Cytokine
production was determined by enzyme-linked immunoabsorbent assay 18 hours
after activation. (D) Glucose consumption (measured as glucose remaining in culture
medium after 24 hours of culture, normalized per 106 cells) by DCs cultured without or
with LPS in the absence (-) or presence of 2-DG or AICAR. Bars represent mean
values SDs from 3 independent replicates. All data are representative of 2 or more
independent experiments.
Figure 5. IL-10 inhibits the metabolic switch to glyco-
lysis induced by TLR agonists. (A) Fold increase in the
glycolytic rate of DCs cultured without or with LPS in the
absence (-) or presence of recombinant IL-10 (r10) or
anti–IL-10R Ab (anti-10R). (B) AMPK phosphorylation in
DCs stimulated with LPS, IL-10, or LPS plus IL-10. DCs
were treated as indicated for 30 minutes, and lysates
were probed by Western blotting with antibodies specific
for phosphorylated AMPK
 (Thr-172), or for total AMPK

or for actin (as loading controls). (C) LPS-induced expres-
sion of CD40 by IL-10/ DCs is inhibited by exogenous
IL-10, 2-DG, and AICAR. CD40 expression at 6 hours
after stimulation was measured by flow cytometry.
(-) denotes unstimulated DCs. Plain numbers represent
the percentage of cells within the positive gate, and bold
italic numbers represent mean fluorescence intensities.
(D) IL-10 and 2-DG are equally potent at inhibiting
LPS-induced cytokine (p40) production. Cytokine levels
in supernatants from cells cultured for 18 hours without
(-) or with LPS, plus minus IL-10 or 2-DG, were measured
by enzyme-linked immunoabsorbent assay. Bars repre-
sent mean values  SDs from 3 independent replicates.
All data are representative of 2 or more independent
experiments. (E) A summary of findings.
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Discussion
DCs play a central role in the induction of host-defense mecha-
nisms. Of critical importance is their ability to rapidly switch from
a resting state to an activated state in response to environmental
danger signals associated with infection or cellular damage. We
report here that TLR signaling, a major pathway for DC activation,
triggers metabolic reprogramming that is essential for full DC
maturation and associated biologic functions. This metabolic
conversion is characterized by a switch from mitochondrial
OXPHOS fueled by the -oxidation of lipids to aerobic glycolysis.
The TLR-stimulated change in DC metabolism, which is similar to
the Warburg metabolism observed in transformed cells, is driven by
the PI3K/Akt pathway and is antagonized by AMPK. The immuno-
suppressive cytokine IL-10, which inhibits TLR-stimulated DC
activation, was found to partially antagonize the LPS-induced
hypophosphorylation of AMPK and, thus, inhibits TLR-stimulated
glycolysis in DCs. Together our data suggest that the PI3K-Akt and
AMPK pathways function in opposing fashions to regulate TLR-
stimulated metabolism and DC activation (Figure 5E). In the
absence of TLR signals, activated AMPK, by favoring OXPHOS
over glycolysis, functions to enforce a metabolic profile incompat-
ible with DC activation. TLR signaling promotes a switch to
glycolytic metabolism by activating PI3K-Akt signaling and antago-
nizing AMPK signaling. IL-10 may function to inhibit glycolysis
and DC activation, in part, by preventing TLR-mediated AMPK
hypophosphorylation. Together our data highlight the importance
of TLR-dependent regulation of metabolism for proper DC matura-
tion and function.
Why do DCs initiate such a dramatic change in their core
metabolism in response to TLR signals? From the standpoint of
bioenergetics, glycolysis is capable of producing ATP less effi-
ciently but more quickly than OXPHOS. Engaging in increased
glycolytic metabolism may function as a protective mechanism to
preserve cellular ATP levels and maintain DC viability during an
immune response. Moreover, the ability to generate ATP anaerobi-
cally would be advantageous in infection/inflammation settings
where oxygen tension can be low. Consistent with this hypoxia
inducible factor-1
 has been reported to enhance LPS-induced
glycolytic activity in DCs.28 The metabolism of glucose to pyruvate
and other metabolites serves the additional function of generating
intermediates for de novo synthesis of amino acids and lipids.25,29
In contrast to the situation in T cells and cancer cells, where the
switch to Warburg metabolism is believed to primarily fuel cell
division,25,30 the Warburg effect in DCs is not linked to cellular
proliferation but rather appears to support the development of
demanding new cellular functions and biosynthetic activities,
including the synthesis and secretion of a broad panel of immune
mediators.
By switching their cellular bioenergetics in favor of glycolytic
metabolism, TLR-activated DCs are increasingly reliant on glucose
for survival and function and become more sensitive to death by
nutrient limitation. This raises the possibility that the signal
transduction pathways that regulate bioenergetics play a central
role not only in early events associated with DC activation but
additionally in the regulation of DC lifespan; such a concept is
consistent with a previous report that Akt is critical for DC survival
after proinflammatory signaling.26 It is important to stress that in
the absence of activation signals, DCs are able to survive ad-
equately in low-glucose conditions, presumably because they are
generating energy through alternate means (ie, -oxidation of
lipids) and have relatively low biosynthetic demands.
Our data strongly implicate the PI3K/Akt pathway in the
TLR-induced regulation of DC metabolism. Previous reports have
shown that TLRs activate PI3K in a myeloid differentiation
primary response gene 88–dependent manner.31 Akt is a major
downstream target of PI3K23 and plays a multifaceted role in
promoting glycolysis by stimulating surface membrane expression
of glucose transporter 1, which by increasing the cytoplasmic
concentration of glucose favors increased glycolysis,24 and by
activating hexokinase and phosphofructokinase, which are rate-
limiting enzymes in glycolysis.25 Growth factor receptors such as
that for GM-CSF also activate PI3K/Akt, and this may account for
the background levels of active Akt we observed in immature
resting DCs, which are grown in this cytokine.15 However, TLR ligation
clearly provides an additional and decisive stimulus for Akt activation
that leads to an increase in the glycolytic rate, which is Akt dependent.
Our data indicate that this aspect of TLR signaling effectively provides
metabolic permission for the enactment of the TLR-initiated signals for
full DC activation transmitted by the mitogen-activated protein kinase
and nuclear factor-B pathways.32
Our data implicate AMPK as an inhibitor of DC activation.
AMPK is activated by at least 3 physiologically activated path-
ways: (1) increases in the AMP/ATP ratio, (2) increases in
intracellular Ca2, and (3) cytokine signaling mediated by the
transforming growth factor-–associated kinase-1.33,34 Among other
functions, AMPK stimulates metabolic pathways that generate
ATP, including fatty acid oxidation and autophagy.33-35 AMPK
activation in immature DCs may enforce a metabolic program of
quiescence that relies primarily on OXPHOS for ATP generation.
By shifting metabolic activity away from glycolysis, AMPK
activation appears to establish a bioenergetic status quo in DCs that
is incompatible with cellular maturation. The rapid down-
regulation of AMPK by TLR signaling, coupled with increased
PI3K/Akt-dependent glycolysis, may be a key step in switching the
bioenergetic state of DCs to one that supports full maturation and
activation. The downstream effects of AMPK activation are
complex, and further work is required to understand how AMPK
regulates TLR-induced DC activation. This is particularly impor-
tant, given that AMPK is a target of a number of widely prescribed
drugs, including metformin, used for the treatment of diabetes.33,34
Recent evidence suggests that metformin can alter the development
of CD8 memory T cells, possibly through the action of AMPK.36
This raises the possibility that drugs approved for metabolic
disorders may have striking implications for immunity and may be
useful for the control of immunologic disorders.
DC activation is targeted by both immune system mediators and
pathogen-derived molecules to control the initiation and extent of
the immune response. Our findings suggest that antiinflammatory
mediators, such as IL-10, may function in part by limiting the
glycolytic switch in DCs that accompanies activation. IL-10 plays a
central role in preventing immunopathology during innate and
adaptive immune responses to pathogens and is a key effector
cytokine of regulatory T cells, which are crucial for self-
tolerance.37,38 Our data show that IL-10 antagonizes TLR-induced
glycolysis that is driven by PI3K/Akt signaling in DCs. It is
tempting to believe that this reflects an effect of IL-10 on the
activation of AMPK pathway, because in our studies IL-10 partially
antagonizes LPS-stimulated AMPK hypophosphorylation. Of inter-
est in this context is that AMPK is activated by IL-6 and leptin,13
cytokines which, like IL-10, signal through a STAT3-dependent
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pathway.39 Future efforts will focus on the relationships between
these cytokines and their effects on metabolic transitions in DCs.
By switching toward a program of glycolytic metabolism,
TLR-activated DCs are increasingly reliant on glucose for survival
and function, and they become more sensitive to death by nutrient
limitation. This raises the possibility that the signal transduction
pathways that regulate bioenergetics play a central role not only in
early events associated with DC activation but additionally in the
regulation of DC lifespan. This view may explain how IL-10, an
inhibitory cytokine shown here to block the TLR-induced switch to
glycolysis, can have such broad effects on the expression of innate
inflammatory responses and adaptive immunity.40 Our data suggest
that the manipulation of metabolic pathways in DCs may provide
mechanisms for broadly inhibiting inflammatory processes and
pathologic cellular function.
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